Zacks Investment Research
08 Jun 2026, 16:52 UTC · 2h ago
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
Zacks Investment Research
08 Jun 2026, 16:52 UTC · 2h ago
Story key points
2 claims · impact-rated
Natera has entered a collaboration with CytoDyn to evaluate ctDNA dynamics and generate molecular data for CytoDyn's metastatic colorectal cancer program. — Partnerships that expand the application of a proprietary diagnostic platform (Signatera) into clinical-stage oncology programs typically drive long-term revenue growth and validation.
+0.30Natera will use its Signatera personalized molecular residual disease test to analyze samples from CytoDyn's CLOVER Phase 2 trial. — Direct application of the product in a clinical trial provides specific utility and a path to broader adoption in drug development.
+0.20Ticker attribution
Model heads
The company announced a strategic collaboration with CytoDyn to expand the application of its Signatera test, leading to a 4.4% share price increase.
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is collaborating with Natera to gain deeper insights into treatment response for its metastatic colorectal cancer program.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Zacks Investment Research
1h ago
